TAM kinases as regulators of cell death.


Journal

Biochimica et biophysica acta. Molecular cell research
ISSN: 1879-2596
Titre abrégé: Biochim Biophys Acta Mol Cell Res
Pays: Netherlands
ID NLM: 101731731

Informations de publication

Date de publication:
05 2021
Historique:
received: 02 01 2021
revised: 19 02 2021
accepted: 22 02 2021
pubmed: 2 3 2021
medline: 20 4 2021
entrez: 1 3 2021
Statut: ppublish

Résumé

Receptor Tyrosine Kinases are critical regulators of signal transduction that support cell survival, proliferation, and differentiation. Dysregulation of normal Receptor Tyrosine Kinase function by mutation or other activity-altering event can be oncogenic or can impact the transformed malignant cell so it becomes particularly resistant to stress challenge, have increased proliferation, become evasive to immune surveillance, and may be more prone to metastasis of the tumor to other organ sites. The TAM family of Receptor Tyrosine Kinases (TYRO3, AXL, MERTK) is emerging as important components of malignant cell survival in many cancers. The TAM kinases are important regulators of cellular homeostasis and proper cell differentiation in normal cells as receptors for their ligands GAS6 and Protein S. They also are critical to immune and inflammatory processes. In malignant cells, the TAM kinases can act as ligand independent co-receptors to mutant Receptor Tyrosine Kinases and in some cases (e.g. FLT3-ITD mutant) are required for their function. They also have a role in immune checkpoint surveillance. At the time of this review, the Covid-19 pandemic poses a global threat to world health. TAM kinases play an important role in host response to many viruses and it is suggested the TAM kinases may be important in aspects of Covid-19 biology. This review will cover the TAM kinases and their role in these processes.

Identifiants

pubmed: 33647320
pii: S0167-4889(21)00046-X
doi: 10.1016/j.bbamcr.2021.118992
pii:
doi:

Substances chimiques

Receptor Protein-Tyrosine Kinases EC 2.7.10.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

118992

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Sean M Post (SM)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Michael Andreeff (M)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America; Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Courtney DiNardo (C)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Joseph D Khoury (JD)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Peter P Ruvolo (PP)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America; Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. Electronic address: pruvolo@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH